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A STUDY OF THE USE OF 5 IODO-2'-DEOXYURIDINE IN
CUTANEOUS HERPES SIMPLEX*
JOSEPH W. BURNETT, M.D.f AND SAMUEL L. KATZ, M.D.t
Recent studies of the effects of 5-bromo- and
5-fluoro-2'-deoxyuridine demonstrated that these
compounds interfered with hoth normal deoxy-
ribonucleic acid (DNA) synthesis as well as
viral DNA synthesis in animal and bacterial
cells (1, 2, 3). A third member of this same series,
5-iodo-2'-deoxyuridine (IDU) was subsequently
found to be an effective inhibitor in vitro of 2
DNA viruses, vaccinia and herpes simplex (4).
With this background, Kaufman et at (5) reported
in 1962 that when a supersaturated aqueous solu-
tion of IDE was placed every two hours in the
conjunctival sac of humans and rabbits with
herpes simplex keratitis, the viral infection sub-
sided markedly within two days.
This effect of IDU on ocular herpes simplex
stimulated a double-blind, controlled study of the
therapeutic value of topically administered IDE
in cuteneous herpes simplex. Twenty-six patients(14 test subjects; 12 controls) with cutaneous
herpes simplex were included in the group studied.
Nine patients were hospitalixed, 17 lived outside
the hospital during the course of the investigation.
The latter were instructed to apply the test creams
to their lesions every two hours while awake for a
total of 8—9 applications daily. Hospitalized
patients received 12 applications during each 24
hours. On the initial visit, each patient was
examined and questioned about the length,
frequency and severity of prior attacks of herpes
simplex, and a viral culture of the lesion was
taken after the involved skin had been washed
with alcohol. Thereafter the lesions were inspected
daily by one of the authors (JWB) and the degree
of progress estimated. A lesion was considered
"cured" when the surface of the skin in the in-
fected area was smooth to the touch. The test
ointment consisted of a water-soluble cream base
containing 0.2% IDE; the placebo ointment
consisted of the water-soluble cream base alone.
The two preparations looked and felt identical
and were packaged in identical one ounce tubes.
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No patient knew the composition of the cream he
was using and, until the study had ended, no
examiner knew which cream had been given to
any patient. Four patients dropped out of the
group after 4, 7, 8, and 20 days of treatment
respectively.
In seven patients (3 test subjects, 4 controls)
at least one diameter of the lesions was greater
than 10 cm. In this group three patients using the
test cream were considered "cured" after treat-
ment for 4, 15, and 15 days respectively (average
11.3 days). Three patients using the placebo
dropped out of the study after 4, 8 and 20 days of
treatment respectively, with only slight improve-
ment. The one control who stayed throughout the
study was pronounced "cured" after 11 days of
treatment.
In 19 patients (11 test subjects, 8 controls), the
greatest diameter in any direction of any lesion
was less than 10 cm. One test subject in this group
left the study after seven days of treatment, with
progress estimated as significant. The herpes
lesions of the remaining ten test subjects were
considered "cured" between 3 )4 and 13 days after
the beginning of treatment (average 7.9 days).
This is a significantly shorter "cure time" than
that of the controls in this group (2 to 48 days;
average 16.2 days). However, the median "cure
time" for the test patients (7 days) was almost
identical with that of the patients who used
placebo (S days). This suggests that any apparent
difference in the average "cure times" reported
here for test subjects and for controls may prob-
ably be attributed to the small sample of patients
studied. Hospital and ambulatory patients did
not differ as far as "cure time" was concerned.
The diagnosis of herpes simplex was confirmed
by the isolation and identification of the virus in
primary human amnion tissue cultures in 19
instances (9 test, 10 control subjects). Five of
these patients (2 test, 3 control) had large lesions(diameter greater than 10 cm). There was no
significant difference between the "cure times"
of the test and control subjects with large lesions.
In the remaining 14 patients, whose largest lesions
were less than 19 cm in diameter, the average
"cure time" was 8.75 days, the median "cure time"
9 days.
Because the response of cutaneous herpes
simplex to 0.2% IDE in the cream base was not
remarkable, tests were made with the following
preparations: 2% IDE in water soluble cream; 2%
IDE in a gel; 0.2% aqueous solution of IDE and
10% IDE in water soluble cream. Each of these
was used by a single patient only and no corre-
sponding placebos were given to control subjects.
The "cure time" of these patients was 4, 6 )4, 6,
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TABLE I
Cure times (days)
Lesion less than 10 cm. Lesion greater than 10 cm.
Trial Control Trial Control
33 2 4t 4*
5 7 15 8'j









* Day at which patient lost to follow-up.
f Negative culture, clinical diagnosis only.
and 15 days respectively. The patient who used
10% IDU cream stated that in the past, with
different therapy, attacks of cutaneous herpes
simplex had subsided within two weeks.
The chief point to emphasixe is that no trial
patient, in either group, recovered in less than
3 ) days. These data suggest that when topically
applied in water soluble preparations at concen-
trations of 0.2, 2.0, and 10%, IDU does not drama-
tically affect the course of cutaneous herpes sim-
plex. Until more is known alsout its effects, this
compound should not be made generally available
for the treatment of this self-limited disease.
Many factors might account for the fact that
herpes keratitis responds remarkably well to IDU
while cutaneous herpes does not. Among these arc
the possibility that IDU is not released from the
ointment bases used; the permeability to IDU of
the skin differs from that of the cornea; and
substances which more readily reach the skin than
the cornea from the blood stream may inactivate
or alter IDU before it has affected viral DNA
synthesis.
Summary: A controlled double-blind study of 26
patients with cutaneous herpes simplex treated
locally with IDU has failed to demonstrate any
therapeutic benefit of this compound in this
condition.
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